BOLT News and Press, Bolt Biotherapeutics Inc. From 12/16/21

REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. stocks finished higher on Friday to close out one of the best weeks since February. Investors took in a consumer price index report that...

Shares of Bolt Biotherapeutics (NASDAQ: BOLT) crashed 55.8% on Monday. The steep decline came after the company presented interim data from a phase 1/2 study evaluating BDC-1001 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress that's being held virtua...

Bolt Biotherapeutics (BOLT -50.7%) has lost its charge today following the release of interim results of phase 1/2 data on BDC-1001 for solid tumors. Early signs of clinical activity were seen in 13 of 40 tumor evaluable subjects. One durable partial response was maintained through one year. ...

Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...

Bolt Biotherapeutics (NASDAQ:BOLT) announces interim clinical data from its Phase 1/2 study of BDC-1001, the company’s lead immune-stimulating antibody conjugate (ISAC) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021. The company reported data from...

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec...

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune...

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidate Demonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition ...